Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entera BioSTU:5DT +5.59%32 Return-on-Tangible-Equity is -118.72% as of Mar. 2026. GuruFocus rates STU:5DT with a GF Score™ of 32/100 and a GF Value™ of €0.21 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,199 Biotechnology companies, Entera Bio ranks worse than 68.39% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Entera Bio's annualized net income for the quarter that ended in Mar. 2026 was €-12.13 Mil. Entera Bio's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €10.22 Mil. Therefore, Entera Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -118.72%.
The historical rank and industry rank for Entera Bio's Return-on-Tangible-Equity or its related term are showing as below:
STU:5DT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -119.17 Med: -103.34 Max: -76.17
Current: -81.8
During the past 11 years, Entera Bio's highest Return-on-Tangible-Equity was -76.17%. The lowest was -119.17%. And the median was -103.34%.
STU:5DT's Return-on-Tangible-Equity is ranked worse than 68.39% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs STU:5DT: -81.80
Entera Bio (STU:5DT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Entera Bio Return-on-Tangible-Equity Related Terms
Entera Bio Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Entera Bio's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5DT vs HRTX, OKYO, EDSA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Entera Bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Entera Bio's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -118.72% mean?
Entera Bio (STU:5DT) has a Return-on-Tangible-Equity of -118.72% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Entera Bio and its competitors. According to the industry distribution chart, Entera Bio ranks #820 out of 1199 companies in the Biotechnology industry, placing it in the top 68.4%.
Is Entera Bio's Return-on-Tangible-Equity too high?
Entera Bio's current Return-on-Tangible-Equity is -118.72%. Based on the distribution chart, Entera Bio ranks #820 out of 1199 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Entera Bio has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Return-on-Tangible-Equity compare to HRTX and OKYO?
According to the Biotechnology industry distribution chart, Entera Bio ranks #820 out of 1199 companies for Return-on-Tangible-Equity. This places Entera Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Entera Bio and its competitors. Entera Bio's current Return-on-Tangible-Equity is -118.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Based on GuruFocus' analysis, Entera Bio (STU:5DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.21, compared to a current price of €1.70 — trading 709.5% above its estimated fair value. The current Return-on-Tangible-Equity is -118.72%. Entera Bio's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Entera Bio (STU:5DT), the current Return-on-Tangible-Equity is -118.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entera Bio (STU:5DT) Overvalued in 2026?
Based on GuruFocus' analysis, Entera Bio stock appears to be overvalued.
The current stock price of €1.70 is trading 709.5% above its estimated GF Value™ of €0.21.
GuruFocus considers Entera Bio to be Significantly Overvalued.
Key valuation signals for STU:5DT:
Return-on-Tangible-Equity: -118.72%
GF Value™: €0.21 vs. price of €1.70 (709.5% above fair value)
No single metric tells the full story. See the STU:5DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
32GF Score
Get the complete analysis for STU:5DT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5DT has been successfully added to your 
